BioSpace News Archive

Q3'21 net revenue of $1.05 billion increased 38% as reported, or 35% in constant currency, compared to Q3'20. Organic, constant-currency net revenue grew 35%, compared to Q3'20. Q3'21 net earnings of $232 million; includes a $184 million gain from the sale of the blow-fill-seal business.

– Topline clinical data from SER-287 Phase 2b study in patients with mild-to-moderate ulcerative colitis expected in mid-2021, microbiome biomarker data anticipated in H2 2021 – – Ongoing enrollment in SER-109 open label study for recurrent C. difficile infection; On track to achieve 300 subject enrollment target in Q3 2021 –

Total product and royalty revenues of $605 million in Q1 2021 (+6% vs Q1 2020) Jakafi ® (ruxolitinib) revenues of $466 million in Q1 2021 (+1% vs Q1 2020); reaffirming full year guidance of $2.125-$2.20 billion Pemazyre ® (pemigatinib) now also approved in Europe and Japan, becoming the first internally discovered product to be globally commercialized by Incyte

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it received a Paragraph IV Notice Letter regarding the submission by a generic manufacturer of an Abbreviated New Drug Application

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for the first quarter ended March 31, 2021, and host a corporate update conference

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will participate in a fireside chat at two virtual investor conferences in May.

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the appointment of Mark L. Alley as Vice President of Sales, effective May 10, 2021.

Carmot Therapeutics, Inc. (Berkeley, CA), a clinical-stage biotechnology company applying its proprietary Chemotype Evolution (CE) technology to discover and develop disease-modifying therapies in metabolic disease and cancer, announced today U.S. Food and Drug Administration (FDA) clearance of an IND application for CT-868, Carmot’s dual GLP-1 and GIP receptor modulator.

Mize shares insights from a real-world journey to transform and unify access to service information globally at the Field Service Medical Virtual Event May 4-5, 2021.

Progenity survey showsmore women know their baby’s “fruit size” than the key indicator of a common pregnancy complication